desipramine has been researched along with Multiple Sclerosis in 2 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind clinical trial involving 28 patients with multiple sclerosis and major depressive disorder, 14 patients were randomly assigned to a 5-week trial of desipramine and individual psychotherapy and 14 to placebo plus psychotherapy." | 5.06 | Antidepressant pharmacotherapy of depression associated with multiple sclerosis. ( Schiffer, RB; Wineman, NM, 1990) |
| "Both desipramine and paroxetine show a trend towards efficacy in depression in MS the short term, but both treatments were associated with adverse effects, with significantly more patients treated with paroxetine suffering from nausea or headache." | 4.87 | Pharmacologic treatment of depression in multiple sclerosis. ( De Keyser, J; Glazenborg, A; Koch, MW; Mostert, J; Uyttenboogaart, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koch, MW | 1 |
| Glazenborg, A | 1 |
| Uyttenboogaart, M | 1 |
| Mostert, J | 1 |
| De Keyser, J | 1 |
| Schiffer, RB | 1 |
| Wineman, NM | 1 |
1 review available for desipramine and Multiple Sclerosis
| Article | Year |
|---|---|
Pharmacologic treatment of depression in multiple sclerosis.
Topics: Adult; Antidepressive Agents; Depression; Desipramine; Humans; Multiple Sclerosis; Paroxetine; Rando | 2011 |
1 trial available for desipramine and Multiple Sclerosis
| Article | Year |
|---|---|
Antidepressant pharmacotherapy of depression associated with multiple sclerosis.
Topics: Adult; Aged; Depressive Disorder; Desipramine; Double-Blind Method; Female; Humans; Male; Middle Age | 1990 |